Immuneering (IMRX) Accumulated Expenses (2020 - 2026)

Immuneering's Accumulated Expenses history runs 7 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 9.58% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 9.58% YoY), while the FY2025 annual figure was $7.8 million, up 57.69% from the prior year.
• Accumulated Expenses was $3.1 million for Q1 2026 at Immuneering, down from $7.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $7.8 million in Q4 2025 to a low of $48102.0 in Q2 2022.
• Historically, Accumulated Expenses has averaged $3.9 million across 5 years, with a median of $3.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses sank 98.55% in 2022, then surged 4945.32% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $4.5 million in 2022, then grew by 14.95% to $5.2 million in 2023, then dropped by 3.88% to $5.0 million in 2024, then jumped by 57.69% to $7.8 million in 2025, then plunged by 60.93% to $3.1 million in 2026.
• The last three Accumulated Expenses figures came in at $3.1 million (Q1 2026), $7.8 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.